Related references
Note: Only part of the references are listed.Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michael Duruisseaux et al.
ONCOTARGET (2017)
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
Meghan Shea et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Michael Thomas et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer
Gerold Bepler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer
Luc Friboulet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
S. Postel-Vinay et al.
ONCOGENE (2013)
Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients
C. M. Choi et al.
ANNALS OF ONCOLOGY (2012)
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
W. E. Pierceall et al.
ANNALS OF ONCOLOGY (2012)
Prognostic Role of ERCC1 in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Joshua A. Roth et al.
CLINICAL LUNG CANCER (2011)
Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations
Richard A. Hubner et al.
PLOS ONE (2011)
High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients
Shengxiang Ren et al.
CANCER INVESTIGATION (2010)
Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine
Bente Holm et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy
Hyun Woo Lee et al.
LUNG CANCER (2009)
Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer
L. Taillade et al.
ANNALS OF ONCOLOGY (2007)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Ken A. Olaussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
GR Simon et al.
CHEST (2005)
Small interfering RNA-induced suppression of ERM enhances sensitivity of human cancer cells to cisplatin
IY Chang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Share Paper
